Latest Product Development News

AnteoTech has secured independent validation for its Ultranode™ 95 silicon anode in commercial drone battery cells, launched a new battery additive, and strengthened its cash position with a A$10 million capital raise.

Ovanti appoints two early Afterpay executives to its Advisory Board as it prepares to relaunch its BNPL platforms IOUPAY and myIOU, targeting rapid growth in Southeast Asia and beyond.

ECS Botanics delivered a fourth consecutive quarter of positive operating cash flow in Q4 FY26, with a full-year turnaround of $5.9 million. The company’s branded B2C revenue surged 31% year-on-year, supported by product launches and European market expansion.

TradeWindow Holdings reported a 20% increase in trading revenue to $9.6 million and improved its EBITDA loss to $1.2 million, while advancing its AI-driven FreightAI platform on track for a 2027 commercial release.

Regis Resources has boosted its FY27 gold production guidance to 360-400koz, driven by higher output at Duketon and sustained growth capital investment.

Immuron Limited reported a 6% increase in FY26 sales to AUD 7.7 million, driven by strong gains in Canada and the US despite mixed Australian performance. Marketing initiatives and retail expansion underpin growth.

Microba Life Sciences has delivered robust FY26 growth in its core microbiome testing business, with revenues up 92% year-on-year and a new GI Navigator product set for launch in September 2026. The company also announced a $7 million annualised cost reduction program as it advances towards cashflow break-even.

Netwealth Group posts a record $135.7 billion in funds under administration for FY26, driven by strong net flows and platform enhancements despite short-term geopolitical jitters.

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

TZ Limited has completed a modest entitlement offer at 3 cents per share, raising approximately $121,000, but a significant shortfall of over 81 million shares remains unallocated. The company plans to place these shortfall shares within three months or let them lapse.

MyEco Group has finalised its operational overhaul, consolidating manufacturing in China and cutting fixed costs to sharpen its focus on sustainable packaging growth.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.